Labcorp (LH) Stock Price, News & Analysis

Company Overview

Laboratory Corporation of America Holdings, known as Labcorp, is a global life sciences company specializing in clinical laboratory testing, drug development services and technology-enabled diagnostics. The company offers a comprehensive menu of routine and esoteric tests through over 2,000 patient service centers and a network of laboratories. Beyond core clinical testing, Labcorp provides central laboratory services, genomics, molecular diagnostics and digital pathology solutions to biopharmaceutical companies, healthcare providers and patients worldwide.

Labcorp’s roots date back to 1978 with the establishment of Roche Biomedical Laboratories. A series of mergers and acquisitions over subsequent decades—including the integration of National Health Laboratories and Unilab in the mid-1990s—led to the formation of Labcorp as it is known today. In 2015, Labcorp expanded its footprint in drug development and central lab services through the acquisition of Covance, bolstering its capabilities in preclinical research, clinical trial management and regulatory support.

Headquartered in Burlington, North Carolina, Labcorp operates in more than 100 countries across North America, Europe, Asia-Pacific and Latin America. The company serves a diverse client base that includes hospitals, physician offices, research institutions and pharmaceutical companies. Labcorp’s extensive global infrastructure encompasses high-throughput clinical laboratories, regional testing facilities and specialized centers for genetic testing and esoteric diagnostics.

Under the leadership of President and Chief Executive Officer Adam H. Schechter, Labcorp continues to pursue innovation in areas such as precision medicine, companion diagnostics and digital health. With a focus on strategic partnerships and investment in automation and data analytics, the company aims to accelerate drug development timelines and enhance patient care through more rapid, accurate and accessible laboratory testing services.

Key Stats

• Today's Range: $256.85 to $260.01
• 50-Day Range: $241.26 to $264.18
• 52-Week Range: $198.96 to $265.72
• Volume: 527,493 shs
• Average Volume: 639,641 shs
• Market Capitalization: $21.72 billion
• P/E Ratio: 29.99
• Dividend Yield: 1.11%
• Price Target: $277.75
• Consensus Rating: Moderate Buy

Labcorp Stock Analysis - MarketRank™

Labcorp scored higher than 89% of companies evaluated by MarketBeat, and ranked 113th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Labcorp has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.56%

Earnings Growth

Earnings for Labcorp are expected to grow by 9.56% in the coming year, from $16.01 to $17.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Labcorp is 29.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Labcorp is 29.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.01.

Price to Earnings Growth Ratio

Labcorp has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Labcorp has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.13% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Labcorp has recently increased by 10.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Labcorp pays a meaningful dividend of 1.12%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Labcorp does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Labcorp is 33.29%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Labcorp will have a dividend payout ratio of 16.42% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

4.13% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Labcorp has recently increased by 10.61%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.27

News Sentiment

Labcorp has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Labcorp this week, compared to 14 articles on an average week.

Search Interest

3 people have searched for LH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Labcorp to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,928,714.00 in company stock.

Percentage Held by Insiders

Only 0.84% of the stock of Labcorp is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LH Stock Analysis - Frequently Asked Questions

How have LH shares performed this year?

Labcorp's stock was trading at $229.32 at the start of the year. Since then, LH stock has increased by 13.1% and is now trading at $259.45.

How were Labcorp's earnings last quarter?

Labcorp Holdings Inc. (NYSE:LH) issued its quarterly earnings data on Tuesday, April, 29th. The medical research company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.11. The firm's revenue for the quarter was up 5.3% on a year-over-year basis.
Read the conference call transcript.

Does Labcorp have any subsidiaries?

Labcorp subsidiaries include Clinical Outreach Laboratory Services, Personal Genome Diagnostics Inc., Toxikon Corporation, Myriad Autoimmune’s Vectra Testing Business, Ovia Health, Visiun, Envigo's nonclinical contract research services business, and more.

Who are Labcorp's major shareholders?

Labcorp's top institutional investors include Czech National Bank (0.02%), Fragasso Financial Advisors Inc (0.01%), Baker Ellis Asset Management LLC (0.01%) and Delphi Management Inc. MA (0.01%). Insiders that own company stock include Adam H Schechter, Glenn A Eisenberg, Brian J Caveney, Lance Berberian, Paul R Kirchgraber, Kerrii B Anderson, Dwight Gary Gilliland, Amy B Summy, Mark S Schroeder, Jonathan P Divincenzo, Der Vaart Sandra D Van and Peter J Wilkinson.
View institutional ownership trends.

How do I buy shares of Labcorp?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Labcorp own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Labcorp investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 4/29/2025
• Record date for 6/11 Dividend: 5/29/2025
• Dividend Payable: 6/11/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:LH
• Previous Symbol: NYSE:LH?
• CIK: 920148
• Web: www.labcorp.com
• Phone: (336) 229-1127
• Fax: 336-513-4510
• Employees: 70,000
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Labcorp: $277.75
• High Price Target: $300.00
• Low Price Target: $230.00
• Potential Upside/Downside: +7.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.65
• Trailing P/E Ratio: 29.99
• Forward P/E Ratio: 16.21
• P/E Growth: 1.63
• Net Income: $746 million
• Net Margins: 5.55%
• Pretax Margin: 7.11%
• Return on Equity: 15.27%
• Return on Assets: 6.97%

Debt

• Debt-to-Equity Ratio: 0.68
• Current Ratio: 1.84
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $13.01 billion
• Price / Sales: 1.67
• Cash Flow: $22.58 per share
• Price / Cash Flow: 11.49
• Book Value: $96.27 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 83,700,000
• Free Float: 82,997,000
• Market Cap: $21.72 billion
• Optionable: Optionable
• Beta: 0.82